As a result of its high standards of quality, innovative technologies and clear vision for the future, Aenova has become one of the world’s leading companies for the development, manufacture and marketing of solid, semi-solid and liquid dosage forms
Aenova Holding GmbH was created in 2008 as a result of the merger of Dragenopharm Apotheker Püschl GmbH and SWISS CAPS AG. It is now the parent company of both these organisations within the Aenova Group. Other companies have gradually been incorporated into the Aenova Group, including Euro Vital Pharma and the Temmler Group. CEO and Managing Director of Aenova Holding Gmbh is Heiner Hoppman, interviewed by Pharma World Magazine with Elisabeth Hartmann, Manager Corporate Communication, and Massimiliano Del Frate, Commercial and Logistic Director of Temmler Italia. «With an annual turnover of around EUR 500 million – states Heiner Hoppman – Aenova is one of the world’s leading companies in the pharmaceutical and healthcare industries, with a portfolio of approximately 600 B2B customers. As a result of its high standards of quality, innovative technologies and clear vision for the future, Aenova has become Europe’s leading provider of development, manufacturing and marketing services pharmaceutical products, medical devices and dietary supplements.Its products portfolio consists of solid, semi-solid and liquid dosage forms. Long-term investment in developing products and processes and the ability to react flexibly and swiftly to the changing demands of customers and the market form the basis of the company’s capacity for innovation and guarantee its competitiveness in every business area. Aenova’s expertise and broad portfolio of services enable them to create innovative solutions in all areas, from product development to the production and packaging of medicines and nutritional supplements, being competitive as well in the highest technologies as in the mass market production».